FAHD2CP

Across TCGA pan-cancer cohorts, FAHD2CP RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of FAHD2CP’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FAHD2CP RNA is repressed in tumor relative to normal tissue. In most cancer types FAHD2CP is over-expressed in tumor, although a few such as KIRC and BRCA show the opposite, repressed pattern.

KIRC, LIHC, and BRCA are the cancer types where FAHD2CP tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAHD2CP RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.444	<.001	10	view →
LIHC	Female	All	+0.967	<.001	8	view →
BRCA	Female	II,III,IV	−0.595	<.001	6	view →
THCA	Female	All	−0.508	<.001	6	view →
BLCA	Male	All	−1.161	.004	4	view →
CHOL	Female	All	+2.586	<.001	3	view →
PRAD	All	All	−0.510	<.001	2	view →
LUAD	Female	All	+0.325	.002	2	view →
COAD	All	All	+0.275	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

FAHD2CP–KIRC

Open the KIRC breakdown →